Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero … all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

What's the matter with Massachussetts?

By Megan McArdle
Aug 19 2008, 5:14 PM ET Comment

A belligerent commenter in a recent thread demanded to know why I thought a Massachussetts style reform would stifle innovation, huh?  huh?  Answer:  it's the costs, stupid.  The only way a Massachussets-style mandate can work (the basic idea is also popular in much of Europe) is to force the price low enough that middle-income families will be willing to pay it.  Otherwise you either get non-compliance or repeal.

I know this is going to sound crazy controversial, but the reason that healthcare companies innovate is to make a profit.  And those profits are the first thing that politicians target when they aim to keep costs down.  Sadly, so far there's little recorded success with things like drug and medical equipment development outside of the private sector. 

Dean Baker is proposing that the government should set up a parallel system, to prove how awesome it can be at drug development.  Perhaps surprisingly, I agree--we should have empirical validation of the notion that the market is better at drug development.  But the metric has to be the same as for private companies:  an actual drug that people take.  Drug development is not, as the activists screaming that the NIH "really" invents all the drugs, a simple matter of finding a target that might have some effect on a disease.  Once you've found a target, you need a molecule that will hit it.  And not just any molecule.  It has to be small enough to dose orally, unless you're developing a short-term treatment for something really gnarly like cancer.  It has to make it into the blood at detectable levels without gettng chewed up by the liver.  Once in the blood, it has to do what you expect, which it often doesn't, and not do anything you don't expect, like kill the patients.  It has to be cost-effective to manufacture, which means not only finding reasonably cheap ingredients and a short process, but also something that scales up to produce in industrial quantities--it's no good having a great molecule that can only be produced in .5 milligram lots by a team of devoted chemists.  And oh, it has to improve the lives of enough people to make it worth all the research you've invested.  Once you've nailed all that, and a few things I've forgotten, you have a drug.  Until then, you have a maybe interesting chemical.

Unsurprisingly, I doubt that the government will turn out to be so good at this.  The record of governments at inventing consumer goods is, she said with characteristic understatement, somewhat spotty.


Presented by

More at The Atlantic

translating the Bible—Into an E-Book That Works on Any Phone Translating the Bible—Into an E-Book That Works on Any Phone
Will the Grammys Remain as Bizarre as Always This Year? Our Predictions for 'Music's Biggest Night'
A Brief History of the to-do List and the Psychology of Its Success A Brief History of the To-Do List and the Psychology of Its Success
Video Shows Syrian Anti-Aircraft Tank Firing Randomly Into Peoples' Homes Video Shows Syrian Anti-Aircraft Tank Firing Into Random Homes
Whitney Houston Has Died Whitney Houston's Greatest Hits

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
Special Report
Election 2012 Reuters Election 2012
The destination for full politics coverage, from the primaries to the White House. Read more ›
View All Correspondents

The Biggest Story in Photos

The Civil War, Part 3: The Stereographs

Feb 10, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…

The Graduates

Busted banking careers, crashed consultants, and shrunken incomes: the author attends her 10-year…

Romney’s Business

The Republican contender touts his business experience—but does it really matter?